Neurocrine Biosciences | Le Coût Des Ventes



Cost Of Sales Changement Date
AbbVie USD 4.4B 184M 2024-12
Acadia Pharmaceuticals USD 21.8M 2.95M 2024-12
Agios Pharmaceuticals USD 1.26M 477K 2024-12
ALKERMES USD 62.12M 984K 2024-12
Alnylam Pharmaceuticals USD 102.82M 16.91M 2024-12
Amgen USD 3.11B 198M 2024-12
Biogen USD 583.5M 55.2M 2024-12
BioMarin Pharmaceutical USD 136.14M 52.32M 2024-12
Cytokinetics 463K 79.14M 2024-09
Dynavax Technologies USD 13.41M 326K 2024-12
Exelixis USD 19.96M 2.64M 2025-01
Gilead Sciences USD 1.58B 7M 2024-12
Halozyme Therapeutics USD 42.06M 7.37M 2024-12
Incyte USD 82.38M 2.49M 2024-12
Ionis Pharmaceuticals USD 3.83M 2.76M 2024-12
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Pfizer USD 5.65B 781M 2024-12
Prothena 970K 4.78M 2024-09
Regeneron Pharmaceuticals USD 565.4M 74.3M 2024-12
Repligen USD 87.23M 11.34M 2024-12
Sarepta Therapeutics USD 132.3M 40.61M 2024-12
Teva Pharmaceutical Industries USD 2.11B 18M 2024-12
Ultragenyx Pharmaceutical USD 16.89M 4.13M 2024-12
Vertex Pharmaceuticals USD 423.4M 30.8M 2024-12



Neurocrine Biosciences Le Coût Des Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.